Articles

The distinguished economist talks about the power of entropy in shaping a new economic reality and viewing current events. His new book, Entropy Economics: The Living Basis of Value and Production, challenges flawed mainstream models that lead to distortions and bad policy.

The Utah Project on Antitrust and Consumer Protection hosted a conference on the future of consumer financial services law on October 11, 2024, which was supported by an INET grant.

What Japan, the US, and Europe have in common is growing popular anger over the economy despite high stock prices and low unemployment.

In a fresh release from INET’s book series with Cambridge University Press, renowned German economic historian Carl-Ludwig Holtfrerich uncovers the startling truth behind German currency reform usually hailed as the foundation of the post-war German economic miracle: Ludwig Erhard, who cooperated with the Nazis, unjustly claimed the spotlight, overshadowing the real architect, Edward Tenenbaum.

The biggest factor in accounting for the strength in the economy is the continuing importance of the wealth effect in sustaining consumption by the affluent.

Increasing evidence that the IRA is probably not harming pharmaceutical innovation.

Dr. Phillip Alvelda tells INET’s Lynn Parramore about persistent political and public health failures exposing us to devastating diseases, while vastly underestimating their long-term health effects.

An ensemble of mechanisms enables cloud hegemons (Microsoft, Google, Amazon) to plan the whole AI knowledge and innovation network by weaponizing interdependence in networks.

Stuck in a fog of misleading narratives, most of us don’t see the true extent of COVID’s persisting—and intensifying—threats. INET’s Lynn Parramore talks to Dr. Phillip Alvelda about the dangers we’re missing and the failures of public health agencies to inform and protect us. *This is Part 1 of a two-part interview.

Programs for expedited review may be preferentially reducing the development costs for conditions with lesser disease burden, potentially making investments in addressing the most significant disease burdens even less appealing and exacerbating the market failure further.